LKFT
LAKEFRONT BIOTHERAPEUTIC-ADR
LAKEFRONT BIOTHERAPEUTIC-ADR historical holders
total: 1
Greenlight Capital LAKEFRONT BIOTHERAPEUTIC-ADR transactions over time
- Total transactions:
- 12
- New positions:
- 1
- Added:
- 6
- Reduced:
- 5
- Held since:
- 2021 Q4
- Held for:
- 18 quarters
- Latest activity:
- 2025 Q1
David Einhorn has been an institutional investor in LAKEFRONT BIOTHERAPEUTIC-ADR (LKFT) since 2021 Q4. According to 2026 Q1 report, David Einhorn holds 482,746 shares with a market value of roughly $14.48M representing 0.45% of their equity portfolio. The fund/company first acquired LKFT in 2021 Q4, initially purchasing 185,000 shares. Since the initial investment, Greenlight Capital has made 11 more transactions in this position.
Does David Einhorn still hold LKFT?
Yes, David Einhorn continues to hold LAKEFRONT BIOTHERAPEUTIC-ADR (LKFT). According to their 2026 Q1 report, they maintain a position of 482,746 shares valued at approximately $14.48M, representing 0.45% of their equity portfolio.
When did David Einhorn first invest in LKFT?
David Einhorn first invested in LAKEFRONT BIOTHERAPEUTIC-ADR (LKFT) in 2021 Q4 at the reported quarter-end price of $55.13 per share, acquiring 185,000 shares in their initial purchase.
What is David Einhorn's average cost basis for LKFT?
Based on historical transaction data, David Einhorn's estimated cost basis for LAKEFRONT BIOTHERAPEUTIC-ADR (LKFT) is approximately $37.88 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $37.88
- Weighted AVG sell price:
- $55.86
LKFT transactions history by Greenlight Capital
12 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q1
|
0.61%
|
482,746
|
$25.12
|
$12,126,580
|
+0.71% (+3,383)
|
+0%
|
|
2024 Q3
|
0.57%
|
479,363
|
$28.79
|
$13,800,860
|
+104.13% (+244,535)
|
+0.29%
|
|
2024 Q2
|
0.28%
|
234,828
|
$24.78
|
$5,819,038
|
+46.93% (+75,000)
|
+0.09%
|
|
2024 Q1
|
0.24%
|
159,828
|
$32.20
|
$5,146,462
|
-1.69% (-2,750)
|
-0%
|
|
2023 Q4
|
0.32%
|
162,578
|
$40.65
|
$6,608,796
|
+3.96% (+6,200)
|
+0.01%
|
|
2023 Q3
|
0.31%
|
156,378
|
$34.55
|
$5,402,861
|
+4.14% (+6,210)
|
+0.01%
|
|
2023 Q2
|
0.29%
|
150,168
|
$40.66
|
$6,105,832
|
-0.79% (-1,200)
|
-0%
|
|
2023 Q1
|
0.32%
|
151,368
|
$38.64
|
$5,848,859
|
-2.57% (-3,990)
|
-0.01%
|
|
2022 Q4
|
0.48%
|
155,358
|
$44.38
|
$6,894,789
|
+6.13% (+8,970)
|
+0.03%
|
|
2022 Q2
|
0.64%
|
146,388
|
$55.80
|
$8,169,000
|
-8.62% (-13,812)
|
-0.05%
|
|
2022 Q1
|
0.63%
|
$62.02
|
-13.41% (-24,800)
|
|||
|
2021 Q4
|
0.62%
|
$55.13
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.